The FDA is preparing what could be the biggest shakeup to vaccine approval standards in years, and it's raising eyebrows across the pharmaceutical industry. Vinay Prasad, who runs the Center for Biologics Evaluation and Research, has circulated an internal memo proposing tougher requirements for how vaccines earn federal clearance—and his reasoning is already sparking intense debate.

What's Driving the Proposed Changes

According to the Washington Post, Prasad's memo cites an internal safety review that examined reported deaths following COVID-19 vaccinations. His team analyzed 96 reported deaths in children from 2021 through 2024 using federal surveillance data and concluded that "no fewer" than 10 were vaccine related. Prasad called this "a profound revelation," writing that "for the first time, the US FDA will acknowledge that COVID-19 vaccines have killed American children."

The data came from the Vaccine Adverse Event Reporting System, a database that collects unverified reports from doctors, families, and others. The CDC emphasizes that VAERS alone can't establish whether a vaccine actually caused a death—it's essentially a signal-detection system, not a proof machine.

The New Framework Takes Shape

Prasad's proposed standards would fundamentally change how vaccine makers approach approvals. Instead of relying primarily on antibody responses as evidence of efficacy, manufacturers would need larger trials demonstrating actual real-world protection. For pneumonia vaccines, companies would have to show reductions in pneumonia cases themselves, not just immune markers.

The memo also promises significantly tighter standards for vaccines administered during pregnancy and for multiple shots given simultaneously. It's a comprehensive rethinking of the current approach, and it has major implications for development timelines.

Industry Concerns About Delays

Current and former FDA staffers are warning that this overhaul could dramatically extend development timelines and potentially discourage new vaccine projects altogether. Larger, longer trials for each indication could delay expansions of existing vaccines to new population groups. Some observers worry that guidance covering routine childhood immunization schedules and annual flu shot strategies might face sweeping revisions.

Translation: vaccines could take longer to reach patients, and some projects might not pencil out financially if the bar gets raised high enough.

The Kennedy Connection

Prasad's direction appears aligned with Health Secretary Robert F. Kennedy Jr., who has built a career questioning modern immunization programs. Kennedy founded a prominent anti-vaccine advocacy group and previously called the coronavirus vaccine "the deadliest ever made." He and senior administration officials have revisited long-discredited claims linking childhood vaccines to autism, drawing sharp criticism from medical organizations.

It's worth noting that Kennedy's appointment was controversial precisely because of this history, and now policy appears to be moving in his preferred direction.

Expert Pushback

Not everyone is convinced by the new analysis. Peter Marks, the former FDA vaccine chief, said earlier reviews found no deaths definitively attributed to COVID-19 shots. Jesse Goodman, another past vaccines director, argued that existing approval rules are already "quite strict."

The CDC has also reported relevant context: at least 25 pediatric COVID-associated deaths occurred among hospitalized children since July 2023. Of the 16 children in that group who were eligible for vaccination, none were fully up to date with their shots.

Market Implications

If these stricter standards take effect, vaccine makers face a tougher road ahead. Pfizer Inc. (PFE) and Moderna Inc. (MRNA) would likely see longer development cycles and higher costs for bringing new vaccines to market. That could weigh on future revenue projections and reshape investor expectations for the vaccine development pipeline.

For companies already navigating a post-pandemic environment where vaccine demand has cooled, adding regulatory hurdles creates another challenge. Investors will be watching to see whether this proposal becomes official policy and how quickly it might be implemented.